Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-01
What Is Sermorelin? Benefits, Research & Safety
A truncated form of natural GHRH that was the first GHRH analogue approved for clinical use, used for GH deficiency diagnosis and treatment.
Also known as:
Sermorelin Acetate
GRF 1-29
Geref
Educational Content Only: This page provides research-based information for educational purposes. Sermorelin is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.
Quick Facts
Category
Hormonal & Endocrine
Half-Life
Approximately 10-20 minutes
UK Status
Not licensed for human use. May be available through compounding pharmacies.
EU Status
Not widely approved; availability varies by country.
Overview
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of the 44-amino acid human growth hormone-releasing hormone (GHRH 1-44). This shortened version retains full biological activity, as the first 29 amino acids contain the sequence necessary for receptor binding and activation.
Unlike direct growth hormone administration, Sermorelin works by stimulating the pituitary gland to produce and release GH naturally. This approach maintains the body's normal feedback mechanisms and produces more physiological pulsatile GH release patterns.
Sermorelin was approved by the FDA in 1997 for the diagnosis and treatment of growth hormone deficiency in children under the brand name Geref. However, it was later withdrawn from the market by the manufacturer for commercial reasons (not safety concerns) and is no longer commercially available in its original pharmaceutical form.
The peptide remains available through compounding pharmacies in some countries and continues to be used in clinical practice for growth hormone optimisation, particularly in adults. It is also widely used in research settings.
Discovery & History
Sermorelin was developed following the isolation and characterisation of natural human GHRH in 1982. When researchers sequenced the natural hormone, they discovered it was a 44-amino acid peptide. Subsequent studies revealed that the N-terminal portion (first 29 amino acids) was sufficient for full biological activity.
This truncated peptide, designated GRF 1-29 or Sermorelin, was developed for therapeutic use because it was easier to synthesise than the full 44-amino acid peptide while retaining equivalent activity.
Sermorelin acetate was approved by the FDA in 1997 under the brand name Geref for diagnosis and treatment of GH deficiency in children. It represented a novel approach—stimulating endogenous GH production rather than replacing GH directly.
In 2008, the manufacturer (EMD Serono) voluntarily withdrew Geref from the market for business reasons rather than safety concerns. The company cited manufacturing challenges and commercial considerations.
Despite the withdrawal of the branded product, Sermorelin has remained available through compounding pharmacies and continues to be used clinically, particularly in age-management medicine and for adult GH optimisation.
Mechanism of Action
Sermorelin works through the natural GHRH receptor pathway:
**GHRH Receptor Binding**
Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary gland. This triggers intracellular signalling cascades (primarily through cAMP) that stimulate growth hormone synthesis and release.
**Pulsatile GH Release**
Because Sermorelin works through natural feedback mechanisms, it produces pulsatile GH release similar to normal physiology. This contrasts with direct GH injection, which can suppress natural GH production.
**Preserved Feedback Regulation**
The pituitary's response to Sermorelin is regulated by normal feedback mechanisms. If GH or IGF-1 levels become too high, somatostatin release increases and suppresses further GH release. This makes overdose with dangerous GH levels unlikely.
**Synergy with GHRPs**
Like other GHRH analogues, Sermorelin can be combined with GHRPs (which work through the ghrelin receptor) for synergistic effects on GH release.
**Stimulation of Pituitary Function**
Some research suggests that long-term Sermorelin use may help maintain or even improve pituitary function, potentially "rejuvenating" the growth hormone axis.
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Physiological stimulation of growth hormone release
- 2Elevated IGF-1 levels through natural mechanisms
- 3Maintenance of normal GH pulsatility and feedback
- 4Potential improvements in body composition
- 5Possible enhancement of sleep quality (GH release during sleep)
- 6Lower risk of excessive GH levels compared to direct GH injection
- 7May support pituitary function long-term
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | 200-300 mcg per dose (based on historical clinical use) |
| Frequency | Once daily, typically at bedtime |
| Duration | Ongoing; often used long-term for GH optimisation |
| Notes | Sermorelin was previously an approved medication. It is still available through compounding pharmacies in some regions. Use should be under medical supervision with appropriate monitoring of GH and IGF-1 levels. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (most common)
| Half-Life | Stability |
|---|---|
| Approximately 10-20 minutes | Lyophilised powder stable when properly stored; reconstituted solution should be refrigerated |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions (redness, swelling, pain)
- Flushing immediately after injection
- Headache
- Dizziness
Rare Risks & Concerns
- Antibody formation (reduced efficacy over time)
- Effects on glucose metabolism
- Theoretical concerns shared with all GH-releasing agents
Contraindications
- Active malignancy
- Pregnancy and breastfeeding
- Hypersensitivity to Sermorelin or GHRH
- Certain brain lesions or tumours affecting the pituitary
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. May be available through compounding pharmacies.
🇪🇺 European Union
Not widely approved; availability varies by country.
Sermorelin was FDA-approved but voluntarily withdrawn from the US market. It remains available through compounding pharmacies in some regions. It is prohibited in competitive sports.
Clinical Studies Summary
Sermorelin for Growth Hormone Deficiency
Clinical studies supporting Sermorelin's use in diagnosing and treating GH deficiency in children.
Various publications from FDA approval processView on PubMed
Sermorelin in Adult GH Deficiency
Research on Sermorelin use in adults for GH optimisation.
Various publicationsView on PubMed
Looking for Sermorelin?
Source research-grade Sermorelin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Research Guides
Peptide Comparisons
Related Peptides
CJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreGHRP-2
A potent growth hormone-releasing peptide that stimulates GH secretion through the ghrelin receptor, with additional effects on appetite and cortisol.
Learn moreTesamorelin
An FDA-approved growth hormone releasing hormone analogue used to reduce excess abdominal fat in HIV patients with lipodystrophy.
Learn more